Disease · MONDO_0005087

respiratory system disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. respiratory system disorder. Diseases, record MONDO_0005087. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005087

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: respiratory system disorder; Open Targets
Open Targets ID: MONDO_0005087; Open Targets
Other names: ALVEOL PNEUMONOPATHY NEC, ALVEOL PNEUMONOPATHY NOS, CHR PUL MANIF D/T RADIAT, Chronic and other pulmonary manifestations due to radiation, DISEASES OF THE RESPIRATORY SYSTEM, Disease of respiratory system (disorder), Disease of respiratory system, NOS, Disorder of respiratory system (disorder), INORG DUST PNEUMOCON NEC, LUNG INVOLV IN OTH DIS, Lung involvement in conditions classified elsewhere, Lung involvement in other diseases classified elsewhere, MEDIASTINUM DISEASE NEC, Other alveolar and parietoalveolar pneumonopathy, Other diseases of mediastinum, not elsewhere classified, Other diseases of respiratory system, Other diseases of respiratory system NOS, Other diseases of respiratory system NOS (disorder), Other diseases of respiratory system, not elsewhere classified, Other diseases of trachea and bronchus, not elsewhere classified, Other respiratory system diseases, Other respiratory system diseases (disorder), Other respiratory system diseases NOS, Other respiratory system diseases NOS (disorder), Other specified alveolar and parietoalveolar pneumonopathies, PNEUMOCONIOSES AND OTHER LUNG DISEASES DUE TO EXTERNAL AGENTS, Pneumoconiosis due to other inorganic dust, RESP COND: EXT AGENT NEC, RESP COND: EXT AGENT NOS, RESP SYSTEM DISEASE NEC, RESP SYSTEM DISEASE NOS, Respiratory conditions due to other and unspecified external agents, Respiratory conditions due to other specified external agents, Respiratory conditions due to unspecified external agent, Respiratory disorder, NOS, Respiratory system diseases NOS, Respiratory system diseases NOS (disorder), Unspecified alveolar and parietoalveolar pneumonopathy, Unspecified disease of respiratory system, [X]Chronic and other pulmonary manifestations due to radiation, [X]Chronic and other pulmonary manifestations due to radiation (disorder), [X]Other diseases of the respiratory system, [X]Other diseases of the respiratory system (disorder), [X]Respiratory conditions due to other specified external agents, [X]Respiratory conditions due to other specified external agents (disorder), [X]Respiratory conditions due to unspecified external agent, [X]Respiratory conditions due to unspecified external agent (disorder), disease of respiratory system, disease or disorder of respiratory system, disorder of respiratory system, respiratory disease, respiratory disorder, respiratory system disease, respiratory system disease or disorder; Open Targets
Disease Ontology: DOID:1579; Disease Ontology
MeSH: D012140; MeSH
NCI Thesaurus: C26871; NCI Thesaurus
Highest stage of its drugs: Approval, for 18 of its 38 drugs, from ATC, DailyMed, PMDA and TTD; Open Targets

Drugs38

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Source
DOXAPRAM	CHEMBL1754	Small molecule	Approval	ATC and TTD	2	Drugs and targets
NIKETHAMIDE	CHEMBL2104607	Small molecule	Approval	ATC	2	Drugs and targets
PENTYLENETETRAZOL	CHEMBL116943	Small molecule	Approval	ATC	2	Drugs and targets
ALMITRINE	CHEMBL1183717	Small molecule	Approval	ATC	1	Drugs and targets
BEMEGRIDE	CHEMBL1214192	Small molecule	Approval	ATC	1	Drugs and targets
COLFOSCERIL PALMITATE	CHEMBL1200737	Small molecule	Approval	ATC	1	Drugs and targets
DIMEFLINE	CHEMBL519364	Small molecule	Approval	ATC	1	Drugs and targets
ETHAMIVAN	CHEMBL1229908	Small molecule	Approval	ATC	1	Drugs and targets
GARENOXACIN MESYLATE	CHEMBL3183451	Small molecule	Approval	PMDA	1	Drugs and targets
IBUPROXAM	CHEMBL292707	Small molecule	Approval	TTD, at withdrawal	1	Drugs and targets

1 to 10 of 38

See all 38 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03843541	A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions	Phase 3	333	2023-01-05	Respiratory Tract Diseases, Abnormal Mucus Secretions	ACETYLCYSTEINE, AMBROXOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02057757	Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness	Phase 2	260	2018-07-31	Severe Acute Respiratory Illness	NITAZOXANIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04391309	COVID-19 and Anti-CD14 Treatment Trial	Phase 2	49	2023-06-15	Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	REMDESIVIR	Its record names the disease	ClinicalTrials.gov
NCT03326063	Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban	Phase 2	38	2023-07-14	Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps	IFETROBAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT06116955	The Application of Balanced Propofol Sedation in Fiberoptic Bronchoscopy		424		Bronchoscopy	MIDAZOLAM, PROPOFOL, SUFENTANIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT03983915	Sedation Strategies for Therapeutic Bronchoscopy 2	Not applicable	80		Bronchoscopy, Sedation	DEXMEDETOMIDINE, REMIFENTANIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05575037	Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease	Phase 2	17		Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps	DUPILUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05031455	Mechanisms of Dupilumab in AERD	Phase 2	16		Aspirin-exacerbated Respiratory Disease	ASPIRIN, DUPILUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03595488	Dupilumab for Aspirin-exacerbated Respiratory Disease	Phase 2	11		Aspirin-exacerbated Respiratory Disease	DUPILUMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nitazoxanide (NTZ) vs Placebo: Number of Participants Reporting Serious Adverse Events (SAEs)	6 of 130	3 of 127	257	NCT02057757	Trial comparisons
Nitazoxanide (NTZ) vs Placebo: Number of Participants Reporting Adverse Events (AEs)	83 of 130	80 of 127	257	NCT02057757	Trial comparisons
Nitazoxanide (NTZ) vs Placebo: deaths from any cause	2 of 130	1 of 127	257	NCT02057757	Trial comparisons
Nitazoxanide (NTZ) vs Placebo: serious adverse events	6 of 130	3 of 127	257	NCT02057757	Trial comparisons
IC14 vs Placebo: deaths from any cause	1 of 20	1 of 20	40	NCT04391309	Trial comparisons
IC14 vs Placebo: serious adverse events	4 of 20	1 of 20	40	NCT04391309	Trial comparisons
Ifetroban vs Placebo: deaths from any cause	0 of 18	0 of 18	36	NCT03326063	Trial comparisons
Ifetroban vs Placebo: serious adverse events	0 of 18	0 of 18	36	NCT03326063	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
30753384	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005087

GET https://conductscience.org/api/diseases/v1/MONDO_0005087/drugs?page=2

API reference For AI assistants